Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

, CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

04:55
11/20/16
11/20
04:55
11/20/16
04:55

American Society of Nephrology to hold a conference

ASN Kidney Week 2016 is being held in Chicago on November 15-20.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

CCXI

ChemoCentryx

$7.98

0.04 (0.50%)

ANTH

Anthera

$1.83

-0.06 (-3.17%)

  • 29

    Nov

RTRX Retrophin
$20.08

-1.31 (-6.12%)

11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
CARA Cara Therapeutics
$11.97

0.27 (2.31%)

12/31/15
PIPR
12/31/15
NO CHANGE
Target $34
PIPR
Overweight
Cara Therapeutics called a top 2016 pick at Piper Jaffray
Piper Jaffray analyst Charles Duncan highlights Cara Therapeutics (CARA) as his top pick going into 2016. The analyst likens the company's position to Neurocrine's (NBIX) last year, which he points out gained 150% at the end of 2014 to present. Cara has "notable value creation" potential from two Phase III read-outs of candidates with a "well-vetted mechanism of action in large-market indications," Duncan tells investors in a New Year's Eve research note. The analyst expects Cara's peak sales to reach four times its current market capitalization. He recommends buying the stock ahead of the Phase III readouts and keeps an Overweight rating on the stock with a $34 price target. Duncan expects the company to begin a pivotal trial of IV'845 in uremic pruritus in early 2016, with data being announced likely in Q4. Cara closed yesterday down 33c to $15.79 with a market cap of just below $440M.
02/26/16
CANT
02/26/16
NO CHANGE
CANT
Delay caused by Cara Therapeutics hold will be short, says Cantor
After Cara announced a clinical hold on the Phase III trial of its IV CR845 drug for post-surgical pain, the firm thinks the hold was unnecessary and does not expect it to delay the drug's advancement for more than three months. Cantor keeps a $28 price target and Buy rating on the shares.
10/13/16
HCWC
10/13/16
INITIATION
Target $20
HCWC
Buy
Cara Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Cara Therapeutics with a Buy rating and $20 price target. The company's CR845 presents an opportunity treat peripheral pain without addiction potential, the analyst contends.
CCXI ChemoCentryx
$7.98

0.04 (0.50%)

ANTH Anthera
$1.83

-0.06 (-3.17%)

11/11/16
SBSH
11/11/16
NO CHANGE
Target $6
SBSH
Buy
Anthera price target lowered to $6 from $10 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Anthera Pharmaceuticals to $6 after the company announced that its Phase III trial failed to meet the primary endpoint in systemic lupus erythematosus. The result is not a "huge surprise" as the program always carried high risk, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on the shares, citing significantly higher conviction for Sollpura. He recommends buying on yesterday's weakness.
07/08/16
07/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Neutral at Wedbush. 2. PayPal (PYPL) initiated with an Overweight at Stephens. 3. GrubHub (GRUB) initiated with an Outperform at Wedbush. 4. Anthera (ANTH) initiated with a Buy at H.C. Wainwright. 5. 58.com (WUBA) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/16
HCWC
07/08/16
INITIATION
Target $10
HCWC
Buy
Anthera initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Anthera with a Buy and $10 price target saying shares are attractive ahead of the Sollpura topline data expected by year-end.
03/29/16
SBSH
03/29/16
NO CHANGE
SBSH
Citi lays out potential targets for next biotech M&A wave
Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).

TODAY'S FREE FLY STORIES

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

MDR

McDermott

$7.13

0.3 (4.39%)

, MDSO

Medidata

$79.90

-0.35 (-0.44%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Breaking Hot Stocks news story on McDermott, Medidata »

McDermott to replace…

MDR

McDermott

$7.13

0.3 (4.39%)

MDSO

Medidata

$79.90

-0.35 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

BASFY

BASF

$95.05

-0.18 (-0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BOBE

Bob Evans

$72.53

0.24 (0.33%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Bob Evans management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

May Chicago Fed National…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

, PVTB

PrivateBancorp

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Medidata to replace PrivateBancorp in S&P 400 at open on 6/26 »

Canadian Imperial Bank of…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

PVTB

PrivateBancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MFG

Mizuho Financial Group

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Mizuho Financial Group management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

LULU

lululemon

$55.37

1.12 (2.06%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
lululemon management to meet with Barclays »

Meeting with CEO Laurent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AYR

Aircastle

$21.17

0.04 (0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

EXLS

ExlService

$55.05

0.15 (0.27%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
ExlService management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NBIX

Neurocrine

$47.35

0.23 (0.49%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

XOXO

XO Group

$17.60

0.1 (0.57%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
XO Group management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

May Durable Goods Orders…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools and…

SAVE

Spirit Airlines

$52.55

0.02 (0.04%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Spirit Airlines management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

May Durable Goods Orders…

04:40
06/26/17
06/26
04:40
06/26/17
04:40
General news
FX Action: The yen is under the cosh »

FX Action: The yen is…

03:10
06/26/17
06/26
03:10
06/26/17
03:10
General news
FX Update: The dollar has traded steady-to-softer »

FX Update: The dollar has…

03:05
06/26/17
06/26
03:05
06/26/17
03:05
General news
FX Action: USD-CAD is softer today »

FX Action: USD-CAD is…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.